Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

BACKGROUND: This investigator-initiated trial provided the justification for the phase III GRID study resulting in worldwide regulatory approval of regorafenib as a third-line therapy for patients with metastatic gastrointestinal stromal tumors (GIST). We report the genotype analyses, long-term safe...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ann Oncol
Main Authors: Ben-Ami, E., Barysauskas, C. M., von Mehren, M., Heinrich, M. C., Corless, C. L., Butrynski, J. E., Morgan, J. A., Wagner, A. J., Choy, E., Yap, J. T., Van den Abbeele, A. D., Solomon, S. M., Fletcher, J. A., Demetri, G. D., George, S.
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2016
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279099/
https://ncbi.nlm.nih.gov/pubmed/27371698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw228
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker